{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:34:30Z","timestamp":1791588870806,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40261-026-01545-z","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:58:48Z","timestamp":1774688328000},"page":"479-487","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Trial Comparison of Dupilumab and Nemolizumab for Prurigo Nodularis FDA-Approved Biologic Therapy Selection in Prurigo Nodularis"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7012-3475","authenticated-orcid":false,"given":"Anna","family":"Robertson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4268-4311","authenticated-orcid":false,"given":"Craig","family":"Rohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"1545_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5307","author":"SG Kwatra","year":"2022","unstructured":"Kwatra SG. Prurigo nodularis. JAMA Dermatol. 2022. https:\/\/doi.org\/10.1001\/jamadermatol.2021.5307.","journal-title":"JAMA Dermatol"},{"key":"1545_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.07.697","author":"AH Huang","year":"2020","unstructured":"Huang AH, Canner JK, Khanna R, et al. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol. 2020. https:\/\/doi.org\/10.1016\/j.jid.2019.07.697.","journal-title":"J Invest Dermatol"},{"issue":"5 Suppl","key":"1545_CR3","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.37765\/ajmc.2023.89366","volume":"29","author":"SS Chisolm","year":"2023","unstructured":"Chisolm SS. A review of the current management and burden of prurigo nodularis in the United States. Am J Manag Care. 2023;29(5 Suppl):S63\u201372. https:\/\/doi.org\/10.37765\/ajmc.2023.89366.","journal-title":"Am J Manag Care"},{"issue":"9","key":"1545_CR4","doi-asserted-by":"publisher","first-page":"e767","DOI":"10.1111\/jdv.20585","volume":"39","author":"F Alinaghi","year":"2025","unstructured":"Alinaghi F, Jensen MB, Elberling J, et al. Worldwide prevalence of prurigo nodularis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2025;39(9):e767\u201371. https:\/\/doi.org\/10.1111\/jdv.20585. (Epub 2025 Feb 4).","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1545_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.182","author":"KA Williams","year":"2020","unstructured":"Williams KA, Huang AH, Belzberg M, et al. Prurigo nodularis: pathogenesis and management. J Am Acad Dermatol. 2020. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.182.","journal-title":"J Am Acad Dermatol"},{"key":"1545_CR6","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2492","author":"RI Kestner","year":"2017","unstructured":"Kestner RI, St\u00e4nder S, Osada N, et al. Acquired reactive perforating dermatosis is a variant of prurigo nodularis. Acta Derm Venereol. 2017. https:\/\/doi.org\/10.2340\/00015555-2492.","journal-title":"Acta Derm Venereol"},{"key":"1545_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.05.029","author":"EM Pogatzki-Zahn","year":"2020","unstructured":"Pogatzki-Zahn EM, Pereira MP, Cremer A, et al. Peripheral sensitization and loss of descending inhibition is a hallmark of chronic pruritus. J Invest Dermatol. 2020. https:\/\/doi.org\/10.1016\/j.jid.2019.05.029.","journal-title":"J Invest Dermatol"},{"key":"1545_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.08.042","author":"K Agelopoulos","year":"2023","unstructured":"Agelopoulos K, Renkhold L, Wiegmann H, et al. Transcriptomic, epigenomic, and neuroanatomic signatures differ in chronic prurigo, atopic dermatitis, and brachioradial pruritus. J Invest Dermatol. 2023. https:\/\/doi.org\/10.1016\/j.jid.2022.08.042.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1545_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jid.2024.06.1276","volume":"145","author":"SG Kwatara","year":"2025","unstructured":"Kwatara SG, Stander S, Yosipovitch G, et al. Pathophysiology of prurigo nodularis: neuroimmune dysregulation and the role of type 2 inflammation. J Invest Dermatol. 2025;145(2):249\u201356.","journal-title":"J Invest Dermatol"},{"key":"1545_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.006","author":"LK Oetjen","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017. https:\/\/doi.org\/10.1016\/j.cell.2017.08.006.","journal-title":"Cell"},{"key":"1545_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/science.1085458","author":"AE Kelly-Welch","year":"2003","unstructured":"Kelly-Welch AE, Hanson EM, Boothby MR, et al. Interleukin-4 and interleukin-13 signaling connections maps. Science (1979). 2003. https:\/\/doi.org\/10.1126\/science.1085458.","journal-title":"Science (1979)"},{"key":"1545_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.3251","author":"D Rodriguez","year":"2023","unstructured":"Rodriguez D, Kwatra SG, Dias-Barbosa C, et al. Patient perspectives on living with severe prurigo nodularis. JAMA Dermatol. 2023. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3251.","journal-title":"JAMA Dermatol"},{"key":"1545_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16309","author":"MP Pereira","year":"2020","unstructured":"Pereira MP, Hoffmann V, Weisshaar E, et al. Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study. J Eur Acad Dermatol Venereol. 2020. https:\/\/doi.org\/10.1111\/jdv.16309.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1545_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.649332","author":"C Zeidler","year":"2021","unstructured":"Zeidler C, Pereira MP, St\u00e4nder S. Chronic prurigo: similar clinical profile and burden across clinical phenotypes. Front Med. 2021. https:\/\/doi.org\/10.3389\/fmed.2021.649332.","journal-title":"Front Med"},{"key":"1545_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16929","author":"C Zeidler","year":"2021","unstructured":"Zeidler C, Pereira MP, Dugas M, et al. The burden in chronic prurigo: patients with chronic prurigo suffer more than patients with chronic pruritus on non-lesional skin. J Eur Acad Dermatol Venereol. 2021. https:\/\/doi.org\/10.1111\/jdv.16929.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1545_CR16","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3571","author":"S Gr\u00fcndel","year":"2020","unstructured":"Gr\u00fcndel S, Pereira MP, Storck M, et al. Analysis of 325 patients with chronic nodular prurigo: clinics, burden of disease and course of treatment. Acta Derm Venereol. 2020. https:\/\/doi.org\/10.2340\/00015555-3571.","journal-title":"Acta Derm Venereol"},{"key":"1545_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.02.259","author":"J Han","year":"2022","unstructured":"Han J, Palomino A, Estupinan B, et al. Psychiatric comorbidity in prurigo nodularis and the impact of socioeconomic status. J Clin Aesthet Dermatol. 2022. https:\/\/doi.org\/10.1016\/j.jid.2021.02.259.","journal-title":"J Clin Aesthet Dermatol."},{"key":"1545_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2015.07.010","author":"D Konda","year":"2015","unstructured":"Konda D, Chandrashekar L, Rajappa M, et al. Serotonin and interleukin-6: association with pruritus severity, sleep quality and depression severity in prurigo nodularis. Asian J Psychiatr. 2015. https:\/\/doi.org\/10.1016\/j.ajp.2015.07.010.","journal-title":"Asian J Psychiatr"},{"key":"1545_CR19","doi-asserted-by":"publisher","unstructured":"St\u00e4nder, Sonja & Pereira, Manuel & Berger, et al. (2020) IFSI-guideline on chronic prurigo including prurigo nodularis. Itch 5. e42-e42. https:\/\/doi.org\/10.1097\/itx.0000000000000042.","DOI":"10.1097\/itx.0000000000000042"},{"key":"1545_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.09.020","author":"AA Qureshi","year":"2019","unstructured":"Qureshi AA, Abate LE, Yosipovitch G, et al. A systematic review of evidence-based treatments for prurigo nodularis. J Am Acad Dermatol. 2019. https:\/\/doi.org\/10.1016\/j.jaad.2018.09.020.","journal-title":"J Am Acad Dermatol"},{"key":"1545_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLINDERMATOL.2025.03.013","author":"SG Brooks","year":"2025","unstructured":"Brooks SG, Yosipovitch G. Prurigo nodularis in 2025: current and emerging treatments. Clin Dermatol. 2025. https:\/\/doi.org\/10.1016\/J.CLINDERMATOL.2025.03.013. (Published online March 17).","journal-title":"Clin Dermatol"},{"key":"1545_CR22","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S188070","author":"EH Kowalski","year":"2019","unstructured":"Kowalski EH, Kneiber D, Valdebran M, et al. Treatment-resistant prurigo nodularis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019. https:\/\/doi.org\/10.2147\/CCID.S188070.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"8","key":"1545_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13899","volume":"17","author":"MR McCann","year":"2024","unstructured":"McCann MR, Kosloski MP, Xu C, et al. Dupilumab: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(8):e13899. https:\/\/doi.org\/10.1111\/cts.13899.","journal-title":"Clin Transl Sci"},{"issue":"14-15","key":"1545_CR24","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1080\/1750743X.2024.2383554","volume":"16","author":"S Prajapati","year":"2024","unstructured":"Prajapati S, Flemming JP, Khan D, et al. The role of nemolizumab in the treatment of atopic dermatitis for the adult population. Immunotherapy. 2024;16(14\u201315):925\u201335. https:\/\/doi.org\/10.1080\/1750743X.2024.2383554. (Epub 2024 Aug 9).","journal-title":"Immunotherapy"},{"issue":"12","key":"1545_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113433","volume":"42","author":"S Takahashi","year":"2023","unstructured":"Takahashi S, Ochiai S, Jin J, et al. Sensory neuronal STAT3 is critical for IL-31 receptor expression and inflammatory itch. Cell Rep. 2023;42(12):113433. https:\/\/doi.org\/10.1016\/j.celrep.2023.113433. (Epub 2023 Nov 28).","journal-title":"Cell Rep"},{"issue":"2","key":"1545_CR26","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jaad.2023.04.056","volume":"89","author":"E Pezzolo","year":"2023","unstructured":"Pezzolo E, Gambardella A, Guanti M, et al. Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: a multicenter, prospective, open-label case series study. J Am Acad Dermatol. 2023;89(2):430\u20132. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.056. (Epub 2023 May 5).","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1545_CR27","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.jaad.2025.08.022","volume":"93","author":"M Metz","year":"2025","unstructured":"Metz M, St\u00e4nder S, Moiin A, et al. Safety and efficacy of barzolvolimab, an anti-KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: a randomized phase 1b intravenous single dose study. J Am Acad Dermatol. 2025;93(6):1596\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2025.08.022. (Epub 2025 Aug 19).","journal-title":"J Am Acad Dermatol"},{"key":"1545_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.4950","author":"S St\u00e4nder","year":"2025","unstructured":"St\u00e4nder S, Yosipovitch G, Sofen H, et al. Vixarelimab in patients with prurigo nodularis: a randomized clinical trial. JAMA Dermatol. 2025. https:\/\/doi.org\/10.1001\/jamadermatol.2025.4950. (Epub ahead of print).","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1545_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61040631","volume":"61","author":"M Bianco","year":"2025","unstructured":"Bianco M, D\u2019Oria F, Falcidia C, et al. New and emerging biologics and JAK inhibitors for the treatment of prurigo nodularis: a narrative review. Medicina (Kaunas). 2025;61(4):631. https:\/\/doi.org\/10.3390\/medicina61040631.","journal-title":"Medicina (Kaunas)"},{"issue":"5","key":"1545_CR30","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.jaad.2019.01.052","volume":"80","author":"S St\u00e4nder","year":"2019","unstructured":"St\u00e4nder S, Kwon P, Hirman J, et al. TCP-102 Study Group. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. J Am Acad Dermatol. 2019;80(5):1395\u2013402. https:\/\/doi.org\/10.1016\/j.jaad.2019.01.052. (Epub 2019 Mar 17).","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1545_CR31","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3461","volume":"100","author":"T Todberg","year":"2020","unstructured":"Todberg T, Skov L, Simonsen S, et al. Efficacy of apremilast in patients with prurigo nodularis: a proof-of-concept study. Acta Derm Venereol. 2020;100(8):adv00118. https:\/\/doi.org\/10.2340\/00015555-3461.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1545_CR32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/jdv.17816","volume":"36","author":"E Weisshaar","year":"2022","unstructured":"Weisshaar E, Szepietowski JC, Bernhard JD, et al. Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase. J Eur Acad Dermatol Venereol. 2022;36(3):453\u201361. https:\/\/doi.org\/10.1111\/jdv.17816. (Epub 2021 Dec 1).","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01545-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01545-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01545-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:39:47Z","timestamp":1776865187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01545-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1545"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01545-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No financial support was received for the conduct of this study or for the preparation or publication of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors declare that they have no conflicts of interest relevant to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable. This study did not involve human participants, animals, or identifiable patient data and was based solely on analysis of publicly available clinical trial information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable. This study did not involve human participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"No datasets were generated or analyzed during the current study. All data discussed are derived from publicly available sources, including ClinicalTrials.gov and published literature.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"A.R. conducted the clinical trial review, analyzed the data, and drafted the manuscript and tables. C.A.R. contributed to study conceptualization, provided critical revisions, and assisted with manuscript editing. All authors read and approved the final manuscript and agree to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}